The Effects of STW 5-II on Duodenal Mucosa and Symptoms in Functional Dyspepsia

NCT07198243 · tracked via the Priya Life Science Belgium tracker

Sponsor

Universitaire Ziekenhuizen KU Leuven

Phase

Phase 4

Started

2025-09-30

Last updated

2025-09-30

Condition(s) studied

Functional Dyspepsia

Investigational drug(s) / intervention(s)

STW 5-IIPlacebo

STW 5-II: STW 5-II is an herbal medicinal product for the symptomatic treatment of functional dyspepsia with main symptoms such as epigastric pain, epigastric burning, postprandial fullness and early satiation, but often also loss of appetite, excessive belching and heartburn. STW5-II consists of six herbal extracts: bitter candy tuft, camomile flower, caraway fruit, melissa leaf, peppermint leaf, and licorice root. STW 5-II will be a solution for oral intake, for the treatment of FD, administered as 20 droplets in liquids, three times daily during 8 weeks. Recommended time of ingestion is just before or with meals. Patients and study staff are blinded for the intervention

Placebo: Matching placebo will be a solution for oral intake, administered as 20 droplets in liquids, three times daily during 8 weeks. Recommended time of ingestion is just before or with meals. Patients and study staff are blinded for the intervention.

Study summary

The goal of this clinical trial is to find out whether a herbal medicine called STW 5-II can help improve gut health and symptoms in adults recently diagnosed with functional dyspepsia (FD)-a condition that causes frequent stomach discomfort, especially after eating.

The main questions it aims to answer are:

Can STW 5-II reduce certain immune cells (eosinophils) in the gut lining? Can it improve symptoms like severe postprandial fullness, bloating, epigastric pain, and improve quality of life?

Researchers will compare STW 5-II to a placebo to see if it helps reduce gut inflammation and ease symptoms.

Participants will:

Take either STW 5-II or a placebo for 8 weeks Provide small samples of gut tissue (via endoscopy) Answer questions about their symptoms and daily life An optional 4-week treatment with STW 5-II will follow for all participants.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients ≥18 years newly to be treated with an FD/PDS diagnosis (Rome IV clinical criteria). * Newly to be treated patients are defined as patients currently not on any ongoing treatment for FD (including OTC medication) for the last 2 weeks. Medications such as PPI or others that may affect GI function and symptom should be stopped prior the trial (min 4 weeks). See list of forbidden medication. * Male or female using contraception or postmenopausal * Witnessed written informed consent * Capable to understand and comply with the study requirements Exclusion Criteria: Inclusion criteria: * Patients ≥18 years newly to be treated with an FD/PDS diagnosis (Rome IV clinical criteria). * Newly to be treated patients are defined as patients currently not on any ongoing treatment for FD (including OTC medication) for the last 2 weeks. Medications such as PPI or others that may affect GI function and symptom should be stopped prior the trial (min 4 weeks). See list of forbidden medication. * Male or female using contraception or postmenopausal * Witnessed written informed consent * Capable to understand and comply with the study requirements Exclusion criteria: * Major active somatic or psychiatric condition that may explain dyspeptic symptoms (stable dose of single antidepressant allowed for psychiatric indication, no limitation for other indications) Predominant symptoms of gastro-esophageal reflux disease (GERD) or irritable bowel syndrome (IBS) * Chronic ppi use. No PPI use for at least the prior 4 weeks before entering the trial- History of major abdominal surgery (except for appendectomy, cholecystectomy or splenectomy) * History or presence of diabetes mellitus type 1 \& type 2, coeliac disease or inflammatory bowel disease * Active malignancy * Known HIV, HBV or HCV infection * Significant alcohol use (\>10 units/weeks) * Females pregnant or lactating * Hypersensitivity against ingredients of STW 5-II or placebo (see annex) * Abnormal baseline laboratory blood values

Primary outcome measure(s)

Difference in duodenal mucosal eosinophil count between baseline and the end of the treatment (week 8) in both arms — 8 weeks
For the primary outcome, the number of eosinophils per square mm tissue will be counted as described by Ceulemans M et al. The numbers of cells will be compared at the end of treatment between both study arms. The baseline values and the delta over time will also be compared between both groups. If necessary, the baseline value can be added as co-variate in the statistical analysis.

Trial sites (1)

Facility	City	Region	Status
University Hospitals Leuven / UZLeuven	Leuven	Belgium

More Universitaire Ziekenhuizen KU Leuven trials in Belgium

A Study to Investigate the Effect of a Meal At 6pm the Day Before the Colonoscopy on the Bowel Cleansing with Plenvu Active, not recruiting

Follow-up and Outcome of Operative Treatment With Decompressive Release Of The Peroneal Nerve Recruiting

GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis Recruiting

Cochlear Implantation for Young Single-sided Deaf Children Active, not recruiting

Comparing XEN®-63 Gel Stent and PRESERFLO® MicroShunt Recruiting

Other trials for the same condition

Bio-electrical Impedance Analysis in Patients With Functional Dyspepsia Recruiting

Budesonide as a Treatment for Functional Dyspepsia Recruiting

Postprandial Distress Itopride Cohort Trial Starting soon

The Prevalence and the Pathophysiological Role of Non-Helicobacter Pylori Helicobacter Spp. in Well-defined Gastric Diseases and (Pre-) Malignancies Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07198243 on ClinicalTrials.gov ↗ ← All trials in Belgium